Seby B. Jones Cancer Center, Boone
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
East Carolina University, Greenville
и уште 4

Се регрутираНабљудувачка студија

Возраст 65 и постари · Сите полови · Ажурирано 29.6.2026 · NCT01137825

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

East Carolina University, Greenville

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 19.5.2026 · NCT06588478

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

University of North Carolina, Chapel Hill

Се регрутираФаза 1

Возраст 13 и постари · Сите полови · Ажурирано 5.5.2026 · NCT04771572

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Wake Forest Baptist Health, Winston-Salem

Се регрутираНабљудувачка студија

Возраст од 18 до 120 · Сите полови · Ажурирано 13.4.2026 · NCT01890486

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Atrium Health /ID# 267219, Charlotte
Atrium Health Wake Forest Baptist Medical Center /ID# 273142, Winston-Salem

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 9.4.2026 · NCT06428019

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Duke University Medical Center, Durham

Се регрутираФаза 4

Возраст 18 и постари · Сите полови · Ажурирано 2.3.2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Duke University Medical Center, Durham

Се регрутираФаза 4

Возраст 18 и постари · Сите полови · Ажурирано 2.3.2026 · NCT06876649

Study of SGR-1505 in Mature B-Cell Neoplasms

Duke University, Durham

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 13.2.2026 · NCT05544019

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

University of North Carolina /ID# 233313, Chapel Hill
Novant Health Presbyterian Medical Center /ID# 230201, Charlotte
Novant Health Forsyth Medical Center /ID# 249533, Winston-Salem

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 9.2.2026 · NCT04895436

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

The University of North Carolina at Chapel Hill, Chapel Hill

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 7.1.2026 · NCT06043674

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Duke University, Durham

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 10.12.2025 · NCT05602363

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

Се регрутираНабљудувачка студија

Возраст од 18 до 120 · Сите полови · Ажурирано 27.10.2025 · NCT01137643

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Durham VA Medical Center, Durham, NC, Durham

Се регрутираФаза 2

Возраст од 18 до 80 · Сите полови · Ажурирано 14.10.2025 · NCT06520098

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

University of North Carolina, Chapel Hill

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 2.10.2025 · NCT05780034

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Duke University, Durham

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 17.7.2025 · NCT04704323

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.